cataract surgery

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Bilateral Cataract

Conditions

Bilateral Cataract

Trial Timeline

Nov 1, 2013 → Mar 1, 2016

NCT ID

NCT02734459

About cataract surgery

cataract surgery is a phase 3 stage product being developed by GenZum Life Sciences for Bilateral Cataract. The current trial status is completed. This product is registered under clinical trial identifier NCT02734459. Target conditions include Bilateral Cataract.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02734459	Phase 3	Completed	Nov 1, 2013	Mar 1, 2016	Bilateral Cataract

Competing Products

3 competing products in Bilateral Cataract

See all competitors

Product	Company	Stage	Hype Score
CGF166	Novartis	Phase 1/2	41
Dexamethasone ophthalmic insert 0.4Mg + 0.2% loteprednol etabonate ophthalmic suspension + olopatadine hydrochloride ophthalmic solution 0.7%	Ocular Therapeutix	Approved	80
ACT-774312 + Placebo	Idorsia	Phase 2	47

Other Products from GenZum Life Sciences

Naftifine hydrochloride 2% + Placebo + Naftin® 2% (Naftifine hydrochloride 2%)Phase 3